Phase 3 Psoriasis Trial, Recruiting NCT06477536 Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. Condition: Psoriasis
Back to Psoriasis

Phase 3 Psoriasis Trial, Recruiting

NCT06477536
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who took part in a previous related study (HB0034-04) and completed at least the Week 12 visit of that study
  • People whose doctor considers them a suitable candidate for ongoing long-term treatment for their condition
  • Men and women of reproductive age who do not plan to have children and are willing to use reliable contraception throughout the study and for 6 months after the last dose of the study drug
  • People who fully understand the study, are willing to sign a consent form, and are able to attend all required study visits and follow-up appointments

Who may not be able to join:

  • People who are currently experiencing an active flare-up of their condition at the time of enrolment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jianzhong Zhang, PhD, Peking University People's Hospital (PKUPH)

Phone: +86 13636638684

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
2 September 2024
Est. completion
30 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety endpoints include the proportion of subjects with TEAEs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov